Free Trial

Celadon Pharmaceuticals (CEL) Competitors

Celadon Pharmaceuticals logo
GBX 13.80 -1.70 (-10.97%)
(As of 07:41 AM ET)

CEL vs. CNSL, FOX, OTT, BCE, CZN, CHT, DVW, BRCI, NPT, and RCI

Should you be buying Celadon Pharmaceuticals stock or one of its competitors? The main competitors of Celadon Pharmaceuticals include Cambridge Nutritional Sciences (CNSL), Fox Marble (FOX), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), NetPlay TV (NPT), and RapidCloud International (RCI). These companies are all part of the "communication" industry.

Celadon Pharmaceuticals vs.

Celadon Pharmaceuticals (LON:CEL) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celadon Pharmaceuticals£11.26K843.96-£5.23M-£0.08-172.50
Cambridge Nutritional Sciences£9.77M0.78-£3.03MN/AN/A

Celadon Pharmaceuticals has a net margin of 0.00% compared to Cambridge Nutritional Sciences' net margin of -3.36%. Cambridge Nutritional Sciences' return on equity of -3.34% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celadon PharmaceuticalsN/A -190.71% -34.40%
Cambridge Nutritional Sciences -3.36%-3.34%-2.36%

10.7% of Celadon Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.2% of Cambridge Nutritional Sciences shares are owned by institutional investors. 65.1% of Celadon Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Cambridge Nutritional Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Celadon Pharmaceuticals has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Comparatively, Cambridge Nutritional Sciences has a beta of 3.89, indicating that its share price is 289% more volatile than the S&P 500.

In the previous week, Celadon Pharmaceuticals had 4 more articles in the media than Cambridge Nutritional Sciences. MarketBeat recorded 4 mentions for Celadon Pharmaceuticals and 0 mentions for Cambridge Nutritional Sciences. Celadon Pharmaceuticals' average media sentiment score of 0.20 beat Cambridge Nutritional Sciences' score of 0.00 indicating that Celadon Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Celadon Pharmaceuticals Neutral
Cambridge Nutritional Sciences Neutral

Celadon Pharmaceuticals received 4 more outperform votes than Cambridge Nutritional Sciences when rated by MarketBeat users.

CompanyUnderperformOutperform
Celadon PharmaceuticalsOutperform Votes
4
100.00%
Underperform Votes
No Votes
Cambridge Nutritional SciencesN/AN/A

Summary

Celadon Pharmaceuticals beats Cambridge Nutritional Sciences on 8 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CEL vs. The Competition

MetricCeladon PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£9.50M£1.17B£5.07B£1.39B
Dividend YieldN/A3.13%4.99%11.73%
P/E Ratio-172.50110.1883.571,549.53
Price / Sales843.961,847.651,220.30209,150.30
Price / Cash3.0510.4339.4632.93
Price / Book3.453.116.932.80
Net Income-£5.23M£159.31M£119.12M£152.70M
7 Day Performance-46.92%-1.13%-1.83%-0.55%
1 Month Performance-45.45%-3.86%-3.64%7.05%
1 Year Performance-87.45%87.64%31.64%91.75%

Celadon Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CEL
Celadon Pharmaceuticals
N/AGBX 13.80
-11.0%
N/A-86.5%£9.50M£11,258.00-172.502,780High Trading Volume
CNSL
Cambridge Nutritional Sciences
N/AGBX 3.20
-8.6%
N/AN/A£7.61M£9.77M-362.103,200
FOX
Fox Marble
N/AGBX 1.35
+14.9%
N/A+0.0%£5.63M£722,064.00-135.0010,600
OTT
Oxford Technology 3 Venture Capital Trust
N/AGBX 34
-19.4%
N/AN/A£2.13M£-85,000.00-12.59203Gap Down
BCE
Beacon Energy
N/AGBX 0
flat
N/A-98.1%£740,000.00N/A-0.3544,600
CZN
Curzon Energy
N/AGBX 0.03
+21.4%
N/A-95.6%£34,000.00N/A-3.4014,700Gap Down
CHT
290005 (CHT.L)
N/AN/AN/AN/A£0.00N/A0.0020,300
DVW
5008 (DVW.L)
N/AN/AN/AN/A£0.00N/A0.00N/AGap Up
BRCI
BlackRock Comms Income Inv Tst
N/AGBX 70.60
-1.0%
N/A+0.0%£0.00N/A0.00N/AHigh Trading Volume
NPT
NetPlay TV
N/AN/AN/AN/A£0.00N/A0.00147,000
RCI
RapidCloud International
N/AN/AN/AN/A£0.00N/A0.0023,000

Related Companies and Tools


This page (LON:CEL) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners